Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Clinical Utility Pilot Of Thyroid GuidePx

16. november 2026 opdateret af: M.D. Anderson Cancer Center

The purpose of this research study is learn about the effects of Thyroid GuidePx® on papillary thyroid cancer treatment recommendations when the test result is disclosed after surgery.

Studieoversigt

Status

Ikke rekrutterer endnu

Intervention / Behandling

Detaljeret beskrivelse

Primary Objectives:

To determine the decision impact of Thyroid GuidePx® when results are disclosed postoperatively, defined across three prespecified decision domains:

  1. Extent of initial surgery (counterfactual): (i) among patients who actually had a total thyroidectomy, through the post-test clinician survey, whether Thyroid GuidePx® results would have changed surgical extent and lobectomy would have been appropriate. This includes patients who underwent intraoperative conversion from lobectomy to total thyroidectomy due to gross extrathyroidal extension or unexpected central nodal metastases. (ii) Among patients who actually had a lobectomy, the post-test clinician survey will record whether, knowing the Thyroid GuidePx® result, total thyroidectomy would have been appropriate (Yes/No), providing a counterfactual measure of potential treatment escalation.
  2. Completion thyroidectomy: whether Thyroid GuidePx® results change the recommendation to perform completion thyroidectomy or not to perform completion thyroidectomy.
  3. Adjuvant RAI: Whether Thyroid GuidePx® results change the recommendation to administer postoperative RAI or not to administer postoperative RAI.

Secondary Objectives:

  1. To estimate the proportion of decision changes within each prespecified domain and the net direction (escalation vs de-escalation).
  2. To explore clinician- and patient-reported drivers of decision change.
  3. To assess postoperative decisional regret following disclosure of Thyroid GuidePx® results using the Decisional Regret Scale (DRS), and to explore associations with surgical extent and molecular risk category.
  4. To compare the proportion of patients who had a completion thyroidectomy in patients who underwent Thyroid GuidePx® testing to historical controls.
  5. To compare recurrence outcomes in patients whose treatment was de-escalated based on Thyroid GuidePx® result to matched historical controls at the same institution.

Undersøgelsestype

Observationel

Tilmelding (Anslået)

78

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Texas
      • Houston, Texas, Forenede Stater, 77030
        • UT MD Anderson
        • Kontakt:
        • Ledende efterforsker:
          • Anastasios Maniakas, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

UT MD Anderson

Beskrivelse

Inclusion Criteria:

disease who can potentially be treated with lobectomy will be recruited to the study. Lobectomy-candidate status is determined by the treating physician using standard institutional criteria (e.g., tumor 1-4 cm, cN0/Nx, no gross ETE). Patients may still undergo total thyroidectomy as part of shared decision-making.

Inclusion criteria:

  • Patients aged 18 years or older at the time of enrollment

  • English-speaking

  • Bethesda V or VI cytology following FNA of a thyroid nodule (papillary thyroid cancer)

  • Preoperative candidacy for lobectomy

    • Tumor 1 - 4 cm in size
    • No known nodal metastasis
    • No gross extrathyroidal extension (ETE) on ultrasound
  • Any of the following intraoperative or surgeon-dependent variations are permitted:

    • Prophylactic ipsilateral central neck dissection performed at the surgeon's discretion
    • Therapeutic central neck dissection for unexpected central node metastases
    • Intraoperative conversion to total thyroidectomy (e.g., gross ETE, multiple large central nodes)
  • Able to undergo intraoperative FNA collection for research testing

Exclusion Criteria:

  • Prior thyroid operation
  • Distant metastatic disease
  • Personal history of thyroid cancer
  • History of whole-body radiation exposure or radiation to the head and neck region
  • Preoperatively known central or lateral lymph node metastasis
  • Receipt of total thyroidectomy is not an exclusion if preoperative features otherwise meet lobectomy-candidate criteria

Patients remain eligible if unexpected central nodal disease is identified intraoperatively or if the surgeon elects to perform a prophylactic ipsilateral central neck dissection, as these scenarios are compatible with initial lobectomy candidacy at MD Anderson.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: CASE_ONLY
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
All Patients

Eligible participants will be identified during standard preoperative evaluation for thyroid nodules or confirmed PTC, following cytological diagnosis (Bethesda V or VI).

Participants will be offered enrollment in this study, in which Thyroid GuidePx® will be performed on an intraoperative FNA (ioFNA) collected during surgery, with results disclosed postoperatively.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Decision Impact. There are three domain-specific endpoints
Tidsramme: Through study completion; an average of 1 year

Extent of initial surgery (counterfactual). (i) Among patients who actually had total thyroidectomy, the post-test clinician survey will record whether, knowing the Thyroid GuidePx® result, would have changed surgical extent. Specifically, if lobectomy would have been appropriate (Yes/No), providing a counterfactual measure of potential de-escalation.

(ii) Among patients who actually had a lobectomy, the post-test clinician survey will record whether, knowing the Thyroid GuidePx® result, total thyroidectomy would have been appropriate (Yes/No), providing a counterfactual measure of potential treatment escalation.

b) Completion thyroidectomy. Proportion with a change in recommendation (Yes→No or No→Yes).

c) Adjuvant RAI. Proportion with a change in recommendation (Yes→No or No→Yes) and intended dose if Yes.

Through study completion; an average of 1 year

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Anastasios Maniakas, MD, UT MD Anderson

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. marts 2027

Primær færdiggørelse (Anslået)

30. juni 2029

Studieafslutning (Anslået)

30. juni 2031

Datoer for studieregistrering

Først indsendt

16. november 2026

Først indsendt, der opfyldte QC-kriterier

16. november 2026

Først opslået (Faktiske)

20. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

20. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner